FDA Peptide Reclassification 2026

September 29, 2023: FDA Places 19 Peptides on Category 2

The FDA updated its interim 503A bulks list to place 19 peptides in Category 2, citing significant safety concerns related to immunogenicity risk, peptide-related impurities, and limited human clinical safety data. The 19 substances were: BPC-157, TB-500 (thymosin beta-4 fragment), Thymosin Alpha-1, GHK-Cu, AOD-9604, CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Epitalon, KPV, MOTS-c, Semax, Selank, Kisspeptin-10, Melanotan II, Cathelicidin (LL-37), Emideltide (DSIP), and PEG-MGF. Licensed 503A compounding pharmacies were prohibited from producing these compounds from that date forward.

2023 to 2025: Industry Challenge and Ongoing Review

The September 2023 action drew substantial pushback from compounding pharmacy associations, clinicians, and patient advocacy groups, who argued that the FDA's safety rationale was disproportionate to the actual risk evidence, and that the restrictions eliminated access to compounds with meaningful clinical utility in individualised patient care. Multiple formal comment submissions, legal challenges, and requests for PCAC review characterised this period. The FDA's Pharmacy Compounding Advisory Committee (PCAC), which advises the FDA on whether specific substances should be on the 503A bulks list, had not yet conducted formal hearings on all 19 substances.

February 27, 2026: RFK Jr. Announces Reclassification

HHS Secretary Robert F. Kennedy Jr. announced publicly that the FDA would move approximately 14 of the 19 restricted peptides back to a status that would permit compounding. The announcement generated significant search interest and media coverage, though as of that date no formal regulatory action had been published, and no effective date had been specified. The announcement preceded formal FDA publication by approximately six weeks.

April 15-16, 2026: Federal Register Notice Published

The FDA published a Federal Register notice formally removing 12 of the 19 peptides from Category 2 of the interim 503A bulks list, with an effective date of approximately April 23, 2026. The notice also announced the scheduling of PCAC advisory committee meetings to formally review those substances for potential addition to Category 1 through rulemaking. Removal from Category 2 lifted the prohibition on compounding but did not constitute formal Category 1 listing.

July 23-24, 2026: PCAC Meetings Scheduled (Group 1)

The PCAC is scheduled to formally review the first group of removed peptides across two meeting days: July 23, 2026 covers BPC-157, KPV, TB-500, and MOTS-c; July 24, 2026 covers Emideltide (DSIP), Semax, and Epitalon. PCAC recommendations are advisory and non-binding; formal addition to Category 1 requires subsequent notice-and-comment rulemaking, a process the FDA has indicated can take more than one year.

Before End of February 2027: PCAC Meetings Scheduled (Group 2)

The FDA has also scheduled PCAC meetings before the end of February 2027 to review the remaining five substances removed from Category 2: GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and PEG-MGF. These five substances are in the same intermediate status as Group 1 (removed from Category 2 prohibition, not yet on Category 1 affirmative list) pending their PCAC hearings.

For Compounding Pharmacies

Licensed 503A compounding pharmacies may now produce the 12 removed substances pursuant to valid prescriptions, provided they source pharmaceutical-grade API from FDA-registered manufacturers and maintain compliant certificates of analysis. The absence from Category 2 removes the federal prohibition; pharmacies should confirm their state pharmacy board's position before commencing production, as state-level oversight can impose additional conditions. Pharmacies awaiting formal Category 1 listing before starting production are acting with an abundance of caution that is legally defensible but not required by the April 2026 action.

For Researchers and Clinicians

The reclassification opens a licensed domestic sourcing pathway for the 12 removed substances that was not legally available under the 2023 Category 2 prohibition. Researchers and prescribers who previously had no compliant domestic compounding option for these compounds now have one, subject to prescription and pharmacy compliance. This does not alter the evidence base for any compound; the clinical research context for each substance is unchanged.

For Patients

Patients whose clinicians had sought to prescribe the reclassified compounds but were unable to obtain them through licensed pharmacies during the Category 2 period now have a licensed domestic compounding pathway available, if a licensed pharmacy in their state chooses to compound the substance. This represents a meaningful access change, particularly for those who previously relied on grey-market or international sources. It does not change whether any of these compounds is appropriate for a given patient; those decisions remain the province of a qualified clinician.

For the International Research Community

The 503A framework governs US compounding pharmacies only. The regulatory status of any of the 12 removed substances in the UK, European Union, Canada, Australia, or any other jurisdiction is governed entirely by the laws of that jurisdiction, independently of US compounding categorisation. Researchers outside the US should consult the relevant regulatory body in their country.